Navigation Links
Two Brands of Pesto Recalled in Quebec, Ontario

The Quebec manufacturer is voluntarily recalling two types of pesto sold in Ontario and Quebec following the warning given by the Canadian Food Inspection Agency to Canadian// consumers not to eat two kinds of pesto – not to eat the Arugula and Blue Cheese pesto and Pesto Rosso Sundried Tomatoes pesto - sold in Ontario and Quebec.

Produced by a company called Pétales et Cie, the affected products were sold in 200 ml glass jars in Quebec and Ontario. The Recall has affected all lot codes and expiry dates of the products.

One of the two types, Blue Cheese pesto may be contaminated with clostridium botulinum, which may cause botulism resulting in respiratory failure, paralysis or death.

The Sundried Tomatoes pesto contains sulphites which are not declared on the label. People with sensitivities to sulphites — compounds used as preservatives — may have serious or life-threatening reactions.

No illnesses have been reported from eating either pesto. However, consumers can call Pétales et Cie at 450-349-3282 or the Canadian Food Inspection Agency at 1-800-442-2342/TTY 1-800-465-7735.



'"/>




Page: 1

Related medicine news :

1. New Research Reveals How We Process Brands And Products
2. Big Brands Ensure Lasting Influences In Dietary Choices.
3. Brain Responds Better to Name Brands
4. Some Brands of Ready Meals Recalled After Glass Scare
5. 90 Brands of Pet Food Recalled from the Market Following Death of 10 Animals
6. A Batch Of Panadol Recalled
7. Azathioprine 50mg Pills Recalled By FDA And Roxane Labs
8. Antibiotic Drug Recalled Following Adverse Effects
9. Toys With Tiny Magnets Recalled
10. Ham And Turkeys Recalled From Honeybaked Food Company Due To Listeria Scare
11. Some Brands of Ready Meals Recalled After Glass Scare
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/19/2017)... ... January 19, 2017 , ... Attorney Robert “RC” Pate ... year donated money to the Triumph Over Kid Cancer foundation. Each year, 175,000 children ... those children. James saw firsthand the effect of the critical funding gap for research ...
(Date:1/19/2017)... ... January 19, 2017 , ... Connecticut Dermatology Group (CDG) ... a highly experienced and compassionate dermatologist. Dr. Kim brings an extensive background in ... “It is with considerable pleasure to welcome back Dr. Kim to the CDG team” ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... hosts the Atlanta Breast Surgery Symposium, a conference where hundreds of surgeons from ... in breast surgery. Covering topics from cosmetic breast augmentation to breast ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... From a ... are released almost daily linking gut health to chronic disease, mental health and general ... Year ” as an important resolution to consider. , For one Charlottesville restaurant, good ...
(Date:1/18/2017)... ... ... The V Foundation for Cancer Research, a top-rated cancer research charity, announced ... to compete in the Boston Marathon on April 17. From first-time participants to ... marathon to join Team V and support the Foundation’s mission to declare victory over ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... , Jan. 18, 2017 The Philadelphia Pediatric Medical ... developing medical devices for children. The Consortium chose ... seed grants of $50,000 each. The devices under ... nerve signals, a hand-operated rapid blood delivery system for emergency ... babies. ...
(Date:1/18/2017)...   Regenicin, Inc. (OTC Bulletin Board: ... development and commercialization of regenerative cell therapies to restore ... the Company,s operating results for 2016 and an outline ... Company described in its recent 10-K filing with the ... The Company,s contract laboratory completed its evaluation of NovaDerm®, ...
(Date:1/18/2017)... 2017  Dermata Therapeutics, LLC, a biotechnology company ... variety of dermatological diseases, announces dosing the first ... Phase 2 acne rosacea study. DMT210 is a ... cytokines in the skin responsible for the inflammation ... This clinical trial, DMT210-003, is a 12-week, ...
Breaking Medicine Technology: